Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:14pm CET

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum™ MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum™ MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt

For full U.S. Prescribing Information for Fanapt, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 21:13:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
02/16VANDA PHARMACEUTICALS : Reports Fourth Quarter 2017 and Full Year 2017 Financial..
AQ
02/15VANDA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
02/14VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
AQ
02/14VANDA PHARMACEUTICALS : Reports Fourth Quarter 2017 and Full Year 2017 Financial..
PR
02/14VANDA PHARMACEUTICALS INC. : to Host Earnings Call
AC
02/08VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2017 Financial ..
AQ
02/01VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2017 Financial ..
AQ
01/30VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2017 Financial ..
PR
01/19VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2017 Re..
AQ
01/11VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
AQ
More news
News from SeekingAlpha
02/153 Biotechs That Resisted The Recent Crash And Why 
02/14Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2017 Results - .. 
02/14Vanda Pharmaceuticals beats by $0.09, beats on revenue 
02/13Notable earnings after Wednesday?s close 
01/19Premarket analyst action - healthcare 
Financials ($)
Sales 2018 187 M
EBIT 2018 -13,0 M
Net income 2018 -15,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 28,34
Capi. / Sales 2018 4,10x
Capi. / Sales 2019 3,15x
Capitalization 768 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,5 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.4.28%768
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637